^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Adenocarcinoma

    Related cancers:
    1d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=690, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    2d
    TroFuse-015: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov)
    P3, N=450, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • docetaxel • irinotecan • Lonsurf (trifluridine/tipiracil) • Jiataile (sacituzumab tirumotecan)
    3d
    STOPGAP: Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, University of California, Irvine | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    paclitaxel • 5-fluorouracil • leucovorin calcium
    3d
    A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=42, Terminated, Prelude Therapeutics | Trial completion date: Apr 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Jan 2026; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date • First-in-human
    5d
    ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, University of California, Irvine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date • Checkpoint inhibition • IO biomarker
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    5d
    Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=168, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    paclitaxel • Cyramza (ramucirumab) • Ziihera (zanidatamab-hrii)
    5d
    NRG-GI007: Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, NRG Oncology | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    carboplatin • paclitaxel • Telomelysin (suratadenoturev)
    6d
    Analysis of Disease Burden, Treatment Patterns, and Prognostic Differences of Different Subtypes of Early/Late-Onset Esophageal Cancer Based on Multi-Databases from a China-US Comparative Perspective and Construction of Survival Prediction Models (ChiCTR2600117727)
    P=N/A, N=1296, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New trial
    6d
    Disitamab Vedotin and Adebrelimab in combination with SOX in the perioperative treatment of HER2-expressing Locally Advanced Esophageal Adenocarcinoma and Esophagogastric Junction Adenocarcinoma: A Prospective, Single-Arm Phase II Study (ChiCTR2500115516)
    P2, N=39, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    oxaliplatin • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    8d
    Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Duke University | N=500 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Tumor mutational burden • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    8d
    OPTIMUS: Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer? (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, University of Surrey
    New trial
    9d
    EA2183: Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (clinicaltrials.gov)
    P3, N=314, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule)
    |
    HER-2 negative
    |
    capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical